{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T23:10:13Z","timestamp":1794093013415,"version":"4.8.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Vinney Foundation, Cleveland, OH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-51442-2","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T13:03:25Z","timestamp":1724763805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["The TGF\u03b2 type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed\/refractory multiple myeloma: a phase 1b trial"],"prefix":"10.1038","volume":"15","author":[{"given":"Ehsan","family":"Malek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5774-4383","authenticated-orcid":false,"given":"Priyanka S.","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthulekha","family":"Swamydas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Daunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4325-1216","authenticated-orcid":false,"given":"Masaru","family":"Miyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3080-8121","authenticated-orcid":false,"given":"Elena","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-2655","authenticated-orcid":false,"given":"James J.","family":"Ignatz-Hoover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leland","family":"Metheny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8364-0617","authenticated-orcid":false,"given":"James J.","family":"Driscoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"51442_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk, N. W. C. J., Pawlyn, C. & Yong, K. L. Multiple myeloma. Lancet 397, 410\u2013427 (2021).","journal-title":"Lancet"},{"key":"51442_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan, A. J. et al. Diagnosis and management of multiple myeloma: a review. JAMA 327, 464\u2013477 (2022).","journal-title":"JAMA"},{"key":"51442_CR3","doi-asserted-by":"crossref","unstructured":"Mateos, M. V., Nooka, A. K. & Larson, S. M. Moving toward a cure for myeloma. Am. Soc. Clin. Oncol. Educ. Book 42, 1\u201312 (2022).","DOI":"10.1200\/EDBK_349603"},{"key":"51442_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrc.2017.63","volume":"17","author":"C Pawlyn","year":"2017","unstructured":"Pawlyn, C. & Morgan, G. J. Evolutionary biology of high-risk multiple myeloma. Nat. Rev. Cancer 17, 543\u2013556 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"51442_CR5","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1182\/blood.2020008734","volume":"139","author":"E Kastritis","year":"2022","unstructured":"Kastritis, E., Terpos, E. & Dimopoulos, M. A. How I treat relapsed multiple myeloma. Blood 139, 2904\u20132917 (2022).","journal-title":"Blood"},{"key":"51442_CR6","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","volume":"33","author":"AH Bazarbachi","year":"2019","unstructured":"Bazarbachi, A. H., Al Hamed, R., Malard, F., Harousseau, J. L. & Mohty, M. Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia 33, 2343\u20132357 (2019).","journal-title":"Leukemia"},{"key":"51442_CR7","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","volume":"24","author":"G Ledergor","year":"2018","unstructured":"Ledergor, G. et al. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat. Med. 24, 1867\u20131876 (2018).","journal-title":"Nat. Med."},{"key":"51442_CR8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.clml.2019.04.018","volume":"19","author":"RZ Orlowski","year":"2019","unstructured":"Orlowski, R. Z. et al. Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups. Clin. Lymphoma Myeloma Leuk. 19, 522\u2013530 (2019).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"51442_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos, M. V. et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 395, 132\u2013141 (2020).","journal-title":"Lancet"},{"key":"51442_CR10","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon, T. et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 1582\u20131596 (2021).","journal-title":"Lancet Oncol."},{"key":"51442_CR11","doi-asserted-by":"crossref","unstructured":"Lannes, R. et al. In multiple myeloma, high-risk secondary genetic events observed at relapse are present from diagnosis in tiny, undetectable subclonal populations. J. Clin. Oncol. 41, 2101987 (2022).","DOI":"10.1200\/JCO.21.01987"},{"key":"51442_CR12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/j.1365-2141.2010.08534.x","volume":"152","author":"N Ghosh","year":"2011","unstructured":"Ghosh, N., Ye, X., Ferguson, A., Huff, C. A. & Borrello, I. Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma. Br. J. Haematol. 152, 593\u2013599 (2011).","journal-title":"Br. J. Haematol."},{"key":"51442_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1200\/JOP.19.00244","volume":"16","author":"A Branagan","year":"2020","unstructured":"Branagan, A., Lei, M., Lou, U. & Raje, N. Current treatment strategies for multiple myeloma. JCO Oncol. Pract. 16, 5\u201314 (2020).","journal-title":"JCO Oncol. Pract."},{"key":"51442_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1200\/OP.21.00032","volume":"17","author":"M Mohan","year":"2021","unstructured":"Mohan, M., Hari, P. & Dhakal, B. Immunotherapy in multiple myeloma-time for a second major paradigm shift. JCO Oncol. Pract. 17, 405\u2013413 (2021).","journal-title":"JCO Oncol. Pract."},{"key":"51442_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","volume":"18","author":"R Derynck","year":"2020","unstructured":"Derynck, R., Turley, S. J. & Akhurst, R. J. TGF\u03b2 biology in cancer progression and immunotherapy. Nat. Rev. Clin. Oncol. 18, 9\u201334 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"51442_CR16","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.annonc.2020.07.009","volume":"31","author":"D Ciardiello","year":"2020","unstructured":"Ciardiello, D., Elez, E., Tabernero, J. & Seoane, J. Clinical development of therapies targeting TGF\u03b2: current knowledge and future perspectives. Ann. Oncol. 31, 1336\u20131349 (2020).","journal-title":"Ann. Oncol."},{"key":"51442_CR17","doi-asserted-by":"publisher","first-page":"a022053","DOI":"10.1101\/cshperspect.a022053","volume":"8","author":"CH Heldin","year":"2016","unstructured":"Heldin, C. H. & Moustakas, A. Signaling receptors for TGF-\u03b2 family members. Cold Spring Harb. Perspect. Biol. 8, a022053 (2016).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"51442_CR18","first-page":"47","volume":"23","author":"HSI Coskun","year":"2006","unstructured":"Coskun, H. S. I. et al. Serum transforming growth factor beta 1 levels in multiple myeloma patients. Turk. J. Hematol. 23, 47\u201352 (2006).","journal-title":"Turk. J. Hematol."},{"key":"51442_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-021-01053-x","volume":"14","author":"BG Kim","year":"2021","unstructured":"Kim, B. G., Malek, E., Choi, S. H., Ignatz-Hoover, J. J. & Driscoll, J. J. Novel therapies emerging in oncology to target the TGF-\u03b2 pathway. J. Hematol. Oncol. 14, 55 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"51442_CR20","doi-asserted-by":"crossref","unstructured":"Jung, S. Y. et al. Population pharmacokinetics of vactosertib, a new TGF-\u03b2 receptor type \u0399 inhibitor, in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 85, 173\u2013183 (2020).","DOI":"10.1007\/s00280-019-03979-z"},{"key":"51442_CR21","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.it.2010.04.002","volume":"31","author":"L Yang","year":"2010","unstructured":"Yang, L., Pang, Y. & Moses, H. L. TGF-\u03b2 and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 31, 220\u2013227 (2010).","journal-title":"Trends Immunol."},{"key":"51442_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104380","volume":"86","author":"AE Metropulos","year":"2022","unstructured":"Metropulos, A. E., Munshi, H. G. & Principe, D. R. The difficulty in translating the preclinical success of combined TGF\u03b2 and immune checkpoint inhibition to clinical trial. EBioMedicine 86, 104380 (2022).","journal-title":"EBioMedicine"},{"key":"51442_CR23","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle, E. & Massagu\u00e9, J. Transforming growth factor-\u03b2 signaling in immunity and cancer. Immunity 50, 924\u2013940 (2019).","journal-title":"Immunity"},{"key":"51442_CR24","doi-asserted-by":"crossref","unstructured":"Principe, D. R. et al. TGF-\u03b2: duality of function between tumor prevention and carcinogenesis. J. Natl Cancer Inst. 106, djt369 (2014).","DOI":"10.1093\/jnci\/djt369"},{"key":"51442_CR25","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1158\/1535-7163.MCT-13-0903","volume":"13","author":"JY Son","year":"2014","unstructured":"Son, J. Y. et al. EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis. Mol. Cancer Ther. 13, 1704\u20131716 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"51442_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05630-5","volume":"14","author":"E Hong","year":"2023","unstructured":"Hong, E. et al. Combination treatment of T1-44, a PRMT5 inhibitor with vactosertib, an inhibitor of TGF-\u03b2 signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors. Cell Death Dis. 14, 93 (2023).","journal-title":"Cell Death Dis."},{"key":"51442_CR27","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1002\/emmm.201302524","volume":"5","author":"JH Yoon","year":"2013","unstructured":"Yoon, J. H. et al. Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes. EMBO Mol. Med. 5, 1720\u20131739 (2013).","journal-title":"EMBO Mol. Med."},{"key":"51442_CR28","doi-asserted-by":"crossref","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"51442_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10928-014-9352-6","volume":"41","author":"JM Harrold","year":"2014","unstructured":"Harrold, J. M. & Abraham, A. K. Ubiquity: a framework for physiological\/mechanism-based pharmacokinetic\/pharmacodynamic model development and deployment. J. Pharmacokinet. Pharmacodyn. 41, 141\u2013151 (2014).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"51442_CR30","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s10637-019-00835-y","volume":"38","author":"SY Jung","year":"2020","unstructured":"Jung, S. Y. et al. Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study. Investig. N. Drugs 38, 812\u2013820 (2020).","journal-title":"Investig. N. Drugs"},{"key":"51442_CR31","doi-asserted-by":"publisher","first-page":"S912","DOI":"10.1016\/j.annonc.2020.08.1959","volume":"31","author":"M Jung","year":"2020","unstructured":"Jung, M. et al. Safety and efficacy of vactosertib, a TGF-\u03b2R1 kinase inhibitor, in combination with paclitaxel in patients with metastatic gastric adenocarcinoma. Ann. Oncol. 31, S912\u20131453P (2020).","journal-title":"Ann. Oncol."},{"key":"51442_CR32","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","volume":"123","author":"PG Richardson","year":"2014","unstructured":"Richardson, P. G. et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 123, 1826\u20131832 (2014).","journal-title":"Blood"},{"key":"51442_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abg2697","volume":"7","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. Sci. Adv. 7, eabg2697 (2021).","journal-title":"Sci. Adv."},{"key":"51442_CR34","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1038\/sj.emboj.7601818","volume":"26","author":"MK Lee","year":"2007","unstructured":"Lee, M. K. et al. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J. 26, 3957\u20133967 (2007).","journal-title":"EMBO J."},{"key":"51442_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/leu.2009.236","volume":"24","author":"H Quach","year":"2010","unstructured":"Quach, H. et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 24, 22\u201332 (2010).","journal-title":"Leukemia"},{"key":"51442_CR36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305\u2013309 (2014).","journal-title":"Science"},{"key":"51442_CR37","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.4049\/jimmunol.1301843","volume":"191","author":"SA Oh","year":"2013","unstructured":"Oh, S. A. & Li, M. O. TGF-\u03b2: guardian of T cell function. J. Immunol. 191, 3973\u20133979 (2013).","journal-title":"J. Immunol."},{"key":"51442_CR38","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamaoncol.2016.0639","volume":"2","author":"AG Sacher","year":"2016","unstructured":"Sacher, A. G. & Gandhi, L. Biomarkers for the clinical use of PD-1\/PD-L1 inhibitors in non\u2013small-cell lung cancer: a review. JAMA Oncol. 2, 1217\u20131222 (2016).","journal-title":"JAMA Oncol."},{"key":"51442_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Y Wolf","year":"2020","unstructured":"Wolf, Y., Anderson, A. C. & Kuchroo, V. K. TIM3 comes of age as an inhibitory receptor. Nat. Rev. Immunol. 20, 173\u2013185 (2020). TIM-3.","journal-title":"Nat. Rev. Immunol."},{"key":"51442_CR40","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","volume":"1","author":"TL Walunas","year":"1994","unstructured":"Walunas, T. L. et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1, 405\u2013413 (1994).","journal-title":"Immunity"},{"key":"51442_CR41","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"D Pardoll","year":"2012","unstructured":"Pardoll, D. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"51442_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.584530","volume":"10","author":"Z Liu","year":"2020","unstructured":"Liu, Z. et al. Study on Tim3 regulation of multiple myeloma cell proliferation via NF-\u03baB signal pathways. Front. Oncol. 10, 584530 (2020).","journal-title":"Front. Oncol."},{"key":"51442_CR43","doi-asserted-by":"crossref","unstructured":"Colak, S. & Ten Dijke, P. Targeting TGF\u03b2 signaling in cancer. Trends Cancer 3, 56\u201371 (2017).","DOI":"10.1016\/j.trecan.2016.11.008"},{"key":"51442_CR44","doi-asserted-by":"publisher","first-page":"609","DOI":"10.4049\/jimmunol.155.2.609","volume":"155","author":"S Rich","year":"1995","unstructured":"Rich, S., Seelig, M., Lee, H. M. & Lin, J. Transforming growth factor beta 1 co-stimulated growth and regulatory function of staphylococcal enterotoxin B-responsive CD8+ T cells. J. Immunol. 155, 609\u2013618 (1995).","journal-title":"J. Immunol."},{"key":"51442_CR45","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1200\/JCO.20.02259","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson, P. G., HORIZON (OP-106) Investigators et al. Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. J. Clin. Oncol. 39, 757\u2013767 (2021).","journal-title":"J. Clin. Oncol."},{"key":"51442_CR46","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"JS Miguel","year":"2013","unstructured":"Miguel, J. S. et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 14, 1055\u20131066 (2013).","journal-title":"Lancet Oncol."},{"key":"51442_CR47","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari, A. et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N. Engl. J. Med. 381, 727\u2013738 (2019).","journal-title":"N. Engl. J. Med."},{"key":"51442_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1059715","volume":"10","author":"PS Rana","year":"2022","unstructured":"Rana, P. S., Soler, D. C., Kort, J. & Driscoll, J. J. Targeting TGF-\u03b2 signaling in the multiple myeloma microenvironment: steering CARs and T cells in the right direction. Front. Cell Dev. Biol. 10, 1059715 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"51442_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/hon.2206","volume":"35","author":"S Aref","year":"2017","unstructured":"Aref, S., Azmy, E. & El-Gilany, A. H. Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma. Hematol. Oncol. 35, 51\u201357 (2017).","journal-title":"Hematol. Oncol."},{"key":"51442_CR50","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000203602","volume":"98","author":"H Kr\u00f6ning","year":"1997","unstructured":"Kr\u00f6ning, H. et al. Overproduction of IL-7, IL-10 and TGF-beta 1 in multiple myeloma. Acta Haematol. 98, 116\u2013118 (1997).","journal-title":"Acta Haematol."},{"key":"51442_CR51","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/annonc\/mdw606","volume":"28","author":"P Musto","year":"2017","unstructured":"Musto, P., International Myeloma Working Group et al. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann. Oncol. 28, 228\u2013245 (2017).","journal-title":"Ann. Oncol."},{"key":"51442_CR52","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012\u2013. Pomalidomide. [Updated 2022 Aug 30]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548343\/."},{"key":"51442_CR53","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00441-011-1246-y","volume":"347","author":"S Dooley","year":"2012","unstructured":"Dooley, S. & ten Dijke, P. TGF-\u03b2 in progression of liver disease. Cell Tissue Res. 347, 245\u2013256 (2012).","journal-title":"Cell Tissue Res."},{"key":"51442_CR54","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","volume":"402","author":"E Platzbecker","year":"2023","unstructured":"Platzbecker, E. et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-na\u00efve, transfusion-dependent lower-risk myelodysplastic syndromes. Lancet 402, 373\u2013385 (2023).","journal-title":"Lancet"},{"key":"51442_CR55","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1365-2141.2011.08703.x","volume":"154","author":"T Sher","year":"2011","unstructured":"Sher, T. et al. A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. Br. J. Haematol. 154, 104\u2013110 (2011).","journal-title":"Br. J. Haematol."},{"key":"51442_CR56","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3390\/cancers12030546","volume":"27","author":"F Petrelli","year":"2020","unstructured":"Petrelli, F. et al. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers 27, 546 (2020).","journal-title":"Cancers"},{"key":"51442_CR57","first-page":"1195","volume":"103","author":"S Jagannath","year":"2005","unstructured":"Jagannath, S. et al. Bortezomib in recurrent and\/or refractory multiple myeloma: initial clinical experience in patients with impaired renal function. Cancer Interdiscip. Int. J. Am. Cancer. Soc. 103, 1195\u20131200 (2005).","journal-title":"Cancer Interdiscip. Int. J. Am. Cancer. Soc."},{"key":"51442_CR58","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/sj.leu.2405087","volume":"22","author":"JF San-Miguel","year":"2008","unstructured":"San-Miguel, J. F. et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 22, 842\u2013849 (2008).","journal-title":"Leukemia"},{"key":"51442_CR59","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","volume":"26","author":"SV Rajkumar","year":"2008","unstructured":"Rajkumar, S. V. et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J. Clin. Oncol. 26, 2171\u20132177 (2008).","journal-title":"J. Clin. Oncol."},{"key":"51442_CR60","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","volume":"8","author":"DA Thomas","year":"2005","unstructured":"Thomas, D. A. & Massagu\u00e9, J. TGF-\u03b2 directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369\u2013380 (2005).","journal-title":"Cancer Cell"},{"key":"51442_CR61","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrc2189","volume":"7","author":"T Hideshima","year":"2007","unstructured":"Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G. & Anderson, K. C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. Cancer 7, 585\u2013598 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"51442_CR62","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/nm1001-1118","volume":"7","author":"L Gorelik","year":"2001","unstructured":"Gorelik, L. & Flavell, R. A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 7, 1118\u20131122 (2001).","journal-title":"Nat. Med."},{"key":"51442_CR63","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.immuni.2006.07.012","volume":"25","author":"JC Marie","year":"2006","unstructured":"Marie, J. C., Liggitt, D. & Rudensky, A. Y. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-\u03b2 receptor. Immunity 25, 441\u2013454 (2006).","journal-title":"Immunity"},{"key":"51442_CR64","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 (2014).","journal-title":"Nature"},{"key":"51442_CR65","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"51442_CR66","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","volume":"176","author":"H Li","year":"2019","unstructured":"Li, H. et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell 176, 775\u2013789 (2019).","journal-title":"Cell"},{"key":"51442_CR67","doi-asserted-by":"publisher","first-page":"93.e1","DOI":"10.1016\/j.urolonc.2017.09.027","volume":"36","author":"I Grenga","year":"2018","unstructured":"Grenga, I. et al. Anti-PD-L1\/TGF\u03b2R2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. Urol. Oncol. 36, 93.e1\u201393.e11 (2018).","journal-title":"Urol. Oncol."},{"key":"51442_CR68","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","volume":"611","author":"RN Amaria","year":"2022","unstructured":"Amaria, R. N. et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 611, 155\u2013160 (2022).","journal-title":"Nature"},{"key":"51442_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0493-9","volume":"7","author":"E Dodagatta-Marri","year":"2019","unstructured":"Dodagatta-Marri, E. et al. \u03b1-PD-1 therapy elevates Treg\/Th balance and increases tumor cell pSmad3 that are both targeted by \u03b1-TGF\u03b2 antibody to promote durable rejection and immunity in squamous cell carcinomas. J. Immunother. Cancer 7, 62 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"51442_CR70","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"51442_CR71","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"51442_CR72","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody, S. et al. GPRC5D-targeted CAR T cells for myeloma. N. Engl. J. Med. 387, 1196\u20131206 (2022).","journal-title":"N. Engl. J. Med."},{"key":"51442_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.957157","volume":"13","author":"PS Rana","year":"2022","unstructured":"Rana, P. S., Murphy, E. V., Kort, J. & Driscoll, J. J. Road testing new CAR design strategies in multiple myeloma. Front. Immunol. 13, 957157 (2022).","journal-title":"Front. Immunol."},{"key":"51442_CR74","unstructured":"Scudiero, D. A. et al. Evaluation of a soluble tetrazolium\/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 48, 4827\u20134833 (1988)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51442-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51442-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51442-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T14:05:29Z","timestamp":1724767529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51442-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51442"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-51442-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3112163\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"assertion":[{"value":"30 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7388"}}